ERBB2 and triple-negative breast carcinoma: Primary tumours from 473 patients (86%) had a known St Gallen subtype according to guidelines from 2013 [15] (Luminal A = 193; Luminal B HER2− = 153; Luminal B HER2+ = 79; HER2+ = 15; triple-negative breast cancer [TNBC] = 33).